Figures & data
Figure 1 Proglucagon contains three homologous hormonal sequences, glucagon/GLP-1/GLP-2, and is separated by intervening peptides IP1/IP2. Proglucagon is processed differentially in pancreas, intestine, and CNS.
![Figure 1 Proglucagon contains three homologous hormonal sequences, glucagon/GLP-1/GLP-2, and is separated by intervening peptides IP1/IP2. Proglucagon is processed differentially in pancreas, intestine, and CNS.](/cms/asset/ab315e55-c1d0-431e-ba19-49af156a6ae6/dceg_a_13906_f0001_c.jpg)
Figure 2 Effect of GLP-2 on murine small intestine. Histological appearance of small intestine epithelium from control (A) and GLP-2-injected (10 days) (B) mice. Reproduced with permission from Drucker et al.Citation11
© Copyright 1996 National Academy of Sciences, USA.
![Figure 2 Effect of GLP-2 on murine small intestine. Histological appearance of small intestine epithelium from control (A) and GLP-2-injected (10 days) (B) mice. Reproduced with permission from Drucker et al.Citation11© Copyright 1996 National Academy of Sciences, USA.](/cms/asset/f963a53f-7e45-4d18-8fa9-96bf0eebcf57/dceg_a_13906_f0002_c.jpg)
Figure 3 Proposed model for the indirect mechanisms of GLP-2 action in the intestine. Expression of the GLP-2R in intestinal endocrine cells (A), intestinal SEMFs (B), and enteric neurons (C) suggests that GLP-2 acts indirectly to produce its diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 to induce intestinal growth and activate crypt cell proliferation. GLP-2-mediated enteric neuronal signaling enhances intestinal blood flow through a mechanism involving NO production and has anti-inflammatory actions through VIP.
Used with permission from Dubé et al, American Journal of Physiology – Endocrinology and Metabolism, Vol 293; E460–E465, 2007.Citation22
![Figure 3 Proposed model for the indirect mechanisms of GLP-2 action in the intestine. Expression of the GLP-2R in intestinal endocrine cells (A), intestinal SEMFs (B), and enteric neurons (C) suggests that GLP-2 acts indirectly to produce its diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 to induce intestinal growth and activate crypt cell proliferation. GLP-2-mediated enteric neuronal signaling enhances intestinal blood flow through a mechanism involving NO production and has anti-inflammatory actions through VIP.Used with permission from Dubé et al, American Journal of Physiology – Endocrinology and Metabolism, Vol 293; E460–E465, 2007.Citation22](/cms/asset/8772c7d3-0b52-454d-b46f-4c2025a45579/dceg_a_13906_f0003_b.jpg)